Unicycive Therapeutics, Inc.

5150 El Camino Real, Suite A-32

Los Altos, CA 94022

 

 

  June 23, 2021

 

VIA EDGAR

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jeffrey Gabor

 

Re: Unicycive Therapeutics, Inc.
    Registration Statement on Form S-1
    Filed May 21, 2021
    File No. 333-256367

 

Ladies and Gentlemen:

 

Reference is made to the acceleration request letter of Unicycive Therapeutics, Inc. (the “Company”) dated June 22, 2021 (the “Acceleration Request”) requesting, pursuant to Rule 461 under the Securities Act of 1933, as amended, the Securities and Exchange Commission (the “Commission”) to accelerate the effective date of the above-referenced Registration Statement and declare the Registration Statement, as then amended, effective as of 5:00 p.m., Eastern Daylight Time, on Thursday, June 24, 2021, or as soon thereafter as practicable.

The Company hereby notifies the Commission of its withdrawal of the Acceleration Request for the above-referenced time until such time as the Company may subsequently request. 

 

 

  UNICYCIVE THERAPEUTICS, INC.
   
  By: /s/ Shalabh Gupta
  Name: Shalabh Gupta
  Title: Chief Executive Officer